- Home
- / Hepalink
Hepalink
Revenue
¥5.3 B
FY, 2025
Hepalink Summary
Company Summary
- Overview
- Shenzhen Hepalink Pharmacetical Group is a pharmaceutical company. It operates in three segments Heparin Industrial Chain, CDMO Services, and Innovative Drug Business. The company focuses on biomacromolecules and gene therapy products, as well as acquiring, developing, and commercializing drugs.
- Type
- Public
- Status
- Active
- Founded
- 1998
- HQ
- Shenzhen, CN | view all locations
- Website
- https://www.hepalink.com/en
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
3 locations detected
Shenzhen, Guang Dong Sheng HQ
China
No. 21, Langshan Road, Songping Mountain, Nanshan District
Shanghai, Shang Hai Shi
China
Room A, 24th Floor, International Ocean Shipping & Finance Center, 720 Pudong Avenue
Hong Kong, Hong Kong Island
Hong Kong
Room 4726, Sun Hung Kai Center, 30 Harbour Road
Hepalink Financials
Summary Financials
- Revenue (Q1, 2026)
- ¥1.3B
- Gross profit (Q1, 2026)
- ¥446.4M
- Net income (Q1, 2026)
- ¥187.4M
- Cash (Q1, 2026)
- ¥1.8B
- EBIT (Q1, 2026)
- ¥305.2M
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026